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Sixty-three patients with life-threatening digitalis intox-
ication were treated with purified fragments of digoxin-
specific antibodies (Fab) obtained from sheep. Twenty-
eight patients developed toxicity as the result of digitalis
ingestion in a suicide attempt,S ingested a large amount
of digoxin accidentally and 30 developed toxicity in the
course of treatment for underlying heart disease. The
dosage of digoxin-specific Fab was calculated to be equl-
molar to the amount of cardiac glycoside in the patient's
body.
Digitalistoxicitywas completelyreversed in most cases,
with onset of effect usually within 30 minutes of admin-
Digitalis intoxication is among the most common adverse
drug reactions in clinical medicine . Severe episodes may be
fatal, particularly in patients with advanced cardiac disease
or in patients who have ingested massive doses of digitalis
accidentally or with suicidal intent. Treatment of digitalis
intoxication has been limited by the absence of a specific
antagonist and by the fact that standard therapeutic modal-
ities are of limited effectiveness when toxicity is severe .
The need to improve treatment of digitalis toxicity stimu-
lated interest in finding a specific means for reversing the
effect of this group of drugs .
Development of Antigen-Binding
Fragments (Fab)
Antibodies to digoxin were successfully produced in 1967
with the hope that they could be used to measure digoxin
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istration of Fab fragments. Unbound and, therefore,
active digoxin serum concentrations decreased to un-
detectable levels within minutes after administration of
the fragments. In all patients who had elevated serum
potassium concentrations caused by massive digitalis
toxicity, treatment with the Fab fragments reversed the
hyperkalemia. There were no obvious adverse reactions
to treatment. Potentially life-threatening digitalis intox-
ication can be rapidly and safely reversed by treatment
with purified digoxin-specific Fab fragments.
o Am Coli Cardio! 1985;5:1l8A-123A)
concentrations in body fluids and also to reverse digitalis
toxicity in human beings (I ). The serum digoxin radioim-
munoassay employing these antibodies was first reported in
1969 (2). Intravenous use of the antibodies to reverse ex-
perimentally induced digoxin toxicity was demonstrated in
dogs in 1971 (3). The mechanism by which they reverse
toxicity appears to be by binding digoxin in extracellular
fluid, causing a decrease in the effective free extracellular
drug concentration. A concentration gradient is thus created
that promotes release of digoxin from receptor sites.
Use of these whole heterologous antibodies , derived ini-
tially from rabbits and subsequently from sheep , was limited
by the known incidence of immediate and delayed hyper-
sensitivity when such foreign proteins are administered to
human beings. Advances in the knowledge of antibody
structure and purification methods during the 1960s and
early 19705 allowed modification of these antibodies to ren-
der them less immunogenic. Digestion of the antibody with
papain yields two antigen-binding fragments (Fab) , each
having a mass of 50,000 daltons, and one crystalline frag-
ment (Fe) from each gamma-G globulin molecule (mass =
150,000 daltons) (4) . Digoxin-specific Fab can be isolated
and purified by passing papain-digested hyperimmune an-
imal serum through a column containing a digitalis glycoside
attached to an inert support matrix (5). This process is re-
ferred to as immunoadsorption and is closely analogous to
affinity chromatography. Only the digoxin-binding frag-
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ments adhere to the column, from which they are eluted as
purifed digoxin-specific Fab .
This purified Fab eluate has numerous advantages over
whole antibody . The smaller size of these fragments permits
them to distribute more rapidly and into a larger distribution
volume within the body (6) , resulting in more rapid and
effective reversal of toxicity (7,8). They also can be excreted
rapidly by glomerular filtration (6) in contrast to the whole
antibody , which is degraded slowly by the reticuloendothe-
lial system. Elimination of the antigenic determinants and
complement-binding site of the Fe portion renders the Fab
portion less immunogenic than intact antibody (6). In ad-
dition , the smaller size of the fragments, their more rapid
excretion and the absence of other protein impurities further
reduce the antigenicity of the preparation .
The ability of digoxin-specific antibodies and antibody
fragments to reverse toxicity in experimental preparations
in vitro and in intact animals has been amply demonstrated.
In erythrocytes with established digoxin-induced inhibition
of sodium and potassium transport, the inhibition was re-
versed by subsequent incubation with digoxin antibody and
antibody fragments (9 ,10). Digoxin induce s an increase in
developed tension in isolated guinea pig atrial muscle strips.
The addition of digoxin antibody fragments reverses this
effect and restores muscle tension to pre-digoxin levels (10).
Addition of toxic levels of digoxin to canine Purkinje fibers
in a tissue bath can cause electrical inexcitabilty . When
digoxin antibodies are added to the bath , membrane char-
acteristics return to normal (II) . Also , prolongation of rabbit
atrioventricular node effective and functional refractory pe-
riods and conduction time caused by digoxin are rapidly
reversed by digoxin antibodies (II).
Intact animal studies of digoxin toxicity have shown that
lethal doses of digoxin in control dogs can be reversed after
the onset of toxic rhythm disturbances by digoxin antibodies
(3) and antibody fragments (7) . When an adequate neu-
tralizing dose is given, advanced toxicity can be reversed ,
and this occurs more rapidly with Fab fragments than with
the whole antibody (7). The inotropic effects of digoxin are
also reversed with more rapid reversal using Fab fragments
than with whole antibody (8), but this occurs over a slower
time course than does arrhythmia reversal. These in vitro
and in vivo studies clearly demon strate the ability of dig-
oxin-specific antibodies and antibody fragments to reverse
the toxic and inotropic effects of digoxin, and also dem-
onstrate the advantage of the purified digoxin-specific Fab
portion over the intact garnma-G globulin antibody .
On the basis of these experimental findin gs , digoxin-
specific Fab fragments were prepared in a form suitable to
treat patients suffering from severe and potentially life-
threatening digitalis intoxication. The first patient treated in
this trial was described in 1976 (12) . Experience with the
first 26 patients was reported in 1982 (13). The present
article summarizes our experience to date.
Methods
The design of the multicenter trial has been described
previously (13) . Briefly, this was a study in 20 geograph-
ically distributed medical centers in the United States in
which digoxin-specific Fab fragments were given in an un-
blinded fashion to patients with potentially life-threatening
cardiac rhythm disturbances or hyperkalemia, or both, caused
by digoxin or digitoxin intoxication. These patients had
failed conventional therapeutic efforts to treat digitalis tox-
icity or, in a few cases , were judged unlikely to respond to
standard measures because of massive intoxication .
Digoxin-specific Fab fragm ents derived from sheep were
administered intravenously, generally over a 15 to 30 minute
period . The dosage of Fab fragments was calculated to be
equimolar to the amount of digoxin in the patient's body .
Estimates of total digoxin load were derived from the med-
ical history or from determinations of serum digoxin con-
centrations, or both .
Therapy with digoxin-specific antibody fragments was
considered effective if life-threatening cardiac arrhythmias
resolved over an accelerated time course , that is, within
minutes to a few hours after treatment. In addition , evidence
was sought for resolution of hyperkalemia caused by tox-
icity-induced inactivation of the cellular Na + -K + adeno sine
triphosphatase (ATPase) pump . Total and free plasma dig-
oxin concentrations were determined when possible.
To assess safety, skin testing and intravenous challenge
with a small dose of purified digoxin-specific antibody frag-
ments were undertaken along with standard laboratory tests .
Patient s were observed carefully for immediate and delayed
hypersensitivity reactions. Clinical circumstances some-
times limited the ability to collect data from laboratory tests.
Results
Patients. After informed con sent was given by the pa-
tient or a responsible relative, 63 patients received digoxin-
spec ific antibody fragments . Fifty-nine had digoxin toxic ity
and 4 had digitoxin toxicity . Thirty-seven were male, 25
were female and I was a true hermaphrodite. The mean age
was 50.6 years (range 3.5 days to 85 years) .
Twenty-eight patients ingested massive amounts of dig-
italis with suicidal intent. Seventeen of these were patients
receiving long-term digitalis therapy , whereas the other II
had no underlying heart disease . An additional five patients,
previously in good health, ingested large amounts of digoxin
as a result of error or accident. Toxicity occurred in 30
patients as a result of error, accident or misadventure in an
effort to treat their underlying heart disease.
Manifestations of digitali s toxicity included nausea and
vomiting in 37 patients, hyperkalemia in 29 patients, second
or third degree atrioventricular block in 41 patients, high
grade ventricular ectopic activity in 46 patients, ventricular
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tachycardia in 41 patients , ventricular fibrillation in 23 pa-
tients and ventricular asystole in I patient.
Previous attempts to reverse digitalis toxicity included
ventricular pacing in 39 patients, direct current cardiover-
sion in 15 patients and administration of atropine in 16
patients, lidocaine in 34 patients and phenytoin in 23 pa-
tients . Twenty-four patients required closed chest cardiopul-
monary resuscitation .
Serum digoxin concentrations of patients at the time of
entry into the study ranged from 2.4 to greater than 100
ng/rnl, with an average concentration of greater than 14.1
ng/ml (in cases where the pretreatment serum digoxin con-
centration was reported only as greater than a stated amount,
that stated amount was used to calculate the mean). All but
9 of the 63 patients had serum digoxin concentrations greater
than 5 ng/ml. The administered dose of digoxin-specific
antibody fragments averaged 520 mg (range 4.0 to 1,600).
Twenty of the patients in this study had normal renal
function before Fab administration . Thirty-one patients had
evidence of abnormal renal function. Renal function was
not reported in 12. The mean (± SO) blood urea nitrogen
and creatinine levels in those patients with abnormal renal
function were 43 ± 20 mg/IOO ml (n = 28) and 2.7 ±
1.2 mg/IOO ml (n = 30), respectively.
Clinical response. Our overall experience is summa-
rized in Figure I . Seven of these 63 patients who received
digoxin-specific antibody fragments were excluded from the
evaluation of efficacy. Two of these patients received doses
Figure 1. Flow diagram summarizing the clinical experience in
63 patients given digoxin-specific antibody fragments.
I 63 patients
Exclusion - 7 patients
2: Inadequate dose
2: Wrong diagnosis
3: Agonal : Ventricular Fibrtlla -
tion or asystole >5 min prior
to Fab or death pronounced
< 15 min .pFab
I Inclusion-56 patients
No Response - 3 patients IPositive Response- I
1: Muit iple drug overdose; 53 patient s
diagnosis of digitalis toxicity
uncertain
2: Severe underl ying heart
disease. diagnosis of digitalis
to xicit y uncertain
Recrudescence of
i-
toxicity - 1 patient
No more drug
available. patient
expired
I Resolution of IToxicity-52 patients
of Fab fragments less than one-tenth the amount calculated
to be needed . Both of these patients died before an adequate
dose was given . An additional three patients were excluded
because they received their digoxin-specific antibody frag-
ments after they were already agonal (which we defined as
no functioning ventricular rhythm for longer than 5 minutes
before initiation of digoxin antibody fragments, or resus-
citation efforts discontinued and death pronounced less than
15 minutes after administration of a therapeutic dose) . Two
other patients were excluded because they did not have clear
evidence of digitalis toxicity. One of these was a patient
receiving therapeutic doses of digoxin who took a suicidal
overdose of furosemide; he was also agonal before antibody
fragments were administered. The second patient had ven-
tricular arrhyth mias and a history of digoxin use , but no
other clinical evidence in favor of the diagnosis of digitalis
toxicity. This patient had no response to the antibody frag-
ments and a pretreatment serum digoxin concentration mea-
surement returned from the laboratory later in the day showed
a low therapeutic concentration .
Of the remaining 56 patients , digitalis toxicity responded
to digoxin-specific antibody fragment therapy in 53 . In one
of these patients. recovery was followed by a return of toxic
manifestations due to a lack of sufficient supply of Fab
fragments . This patient received about half the dose ex-
pected to neutralize the amount of digoxin believed to be
in the patient's body. However, his suicidal ingestion was
massive (25 mg) and he ultimately died from digoxin-in-
duced ventricular fibrillation before more antibody frag-
ments could be obtained. Toxicity resolved completely in
the other 52 patients including the 4 patients with digitoxin
toxicity.
In each of the three patients who showed no response to
the digoxin-specific antibody fragments, the diagnosis of
digitalis toxicity was uncertain. Two of these patients had
an elevated serum digoxin concentration, but also had very
severe underlying heart disease and documented severe ven-
tricular arrhythmias before the serum digoxin concentration
became elevated . A third patient developed a prolonged
episode of ventricular fibrillation after a combined digoxin
and tricyclic antidepressant overdose . She was successfully
resuscitated to a regular rhythm with complete heart block,
but without return of brain function . Digoxin antibody frag-
ments were then administered but had no effect on her heart
block, which in retrospect was considered most likely to be
due to the tricyclic overdose .
Time course of response . Patients usually responded to
the antibody fragments within 30 minutes of administration.
The onset of response was probably affected by such factors
as the speed of administration of the antibody fragments,
the amount of Fab fragments given in relation to the amount
of digoxin ingested and other less well defined factors . In-
fants and young children sometimes responded within minutes.
The response of an adult patient is shown in Figure 2.
He was given 520 mg of digoxi n-specific antibody fragments
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Figure 2. Change in ventricularresponserate of a patient in atrial
fibrillation with a serum digoxin concentration of 4.7 ng/m!. The
patient received 520 mg of digoxin-specific Fab between4: 45 and
5: 15 PM. The onset of effect was rapid, with complete response
occurring within 31/ 2 hours.
after three episodes of ventricular tachycardia requiring di-
rect current cardioversion. This patient also manifested ven-
tricular ectopic beats, atrial fibrillation, nausea and vomit-
ing, a serum potassium concentration of 6.2 mEq/liter and
a serum digoxin concentration of 4.7 ng/m!. No episodes
of ventricular tachycardia occurred after the Fab fragments
were given. He averaged two ventricular ectopic beats/min
until treatment with the antibody fragments, after which
ventricular ectopic activity completely resolved. As can be
seen in Figure 2, his ventricular response was 90 beats/min
before Fab was administered. During Fab infusion, the ven-
tricular rate increased to 120 beats/min, indicating partial
reversal of digoxin effects on atrioventricular conduction.
Response was complete by 3 '12 hours after Fab administration.
Laboratory evaluation. Laboratory evidence for bind-
ing of digoxin or digitoxin by digoxin-specific antibody
fragments was seen in the postadministration serum drug
concentrations. In all six patients in whom it was measured,
the concentration of free and, therefore, active digoxin or
digitoxin decreased to zero or near zero within I to 2 minutes
after administration of the antibody fragments. Total serum
digoxin concentration increased rapidly after administration
of the antibody fragments to values typically 10- to 20-fold
higher than pretreatment levels. Essentially, all of this dig-
oxin was bound to the antibody fragments and was, there-
fore, pharamacologically inactive. A typical serum digoxin
response to administration of digoxin-specific antibody frag-
ments is shown in Figure 3.
Serum potassium concentration, The mean potassium
concentration before treatment with antibody fragments was
5.5 mEq/liter (range 2.4 to 10.3). In 31 patients for whom
serum potassium concentrations were known both before
and after Fab administration, the average pretreatment po-
tassium concentration was 5.8 mEq/liter and the average
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Figure 3. Time course of serum digoxinconcentration beforeFab
administration (e), total serum digoxin concentration after treat-
ment (0) and free serum digoxin concentrations after treatment
(.). Administration of digoxin-specific Fab fragments was started
at0 hours. (Adapted fromRef. 12,withpermission of thepublishers.)
posttreatment level (usually obtained about 4 hours after
start of treatment) was 4.4 mEq/liter (p < 0.01). In all
patients who had elevated serum potassium concentrations,
treatment with digoxin antibody fragments reversed the hy-
perkalemia. Some of these patients received other treatment
for hyperkalemia before administration of the antibody frag-
ments. There was no relation between pretreatment hyper-
kalemia and outcome (Fig. 4). There were no significant
changes in other laboratory variables measured.
Adverse reactions. There were no obvious reactions to
Fab treatment in any of the patients in this tria!. One patient
had slight erythema at the site of skin testing, but no sys-
temic reaction to the therapeutic dose. Several patients de-
veloped fever at various times after administration of the
antibody fragments, but in no case was the timing or the
clinical setting suggestive of a Fab-induced or endotoxin-
induced fever. In all febrile patients, clear evidence of in-
fection existed. There was no evidence of renal deterioration
caused by antibody fragment therapy. No acute hypersen-
sitivity reaction or delayed serum sickness was seen in any
of the patients.
Six patients had clinical evidence of some degree of im-
paired ventricular function several hours to 1 day after
treatment. Although withdrawal of the inotropic support of
digoxin may have added to their preexisting low cardiac
output state, numerous adjustments in fluid volume, diuretic
drug and vasodilator therapy, as well as the frequent oc-
currence of cardiac arrest occurring about the time of treat-
ment in this group, make assessments of causality impos-
sible. In contrast, most patients responded to digoxin antibody
treatment with obvious improvement in their hemodynamic
state coincident with resolution of refractory arrhythmias.
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Figure 4. Serum potassiumconcentration before treatment (stan-
dard therapy or Fab administration) versus patient outcome. De-
picted on the left of the figure is the experienceof Bismuth et al.
(14) from 91 patients using standard therapy for digitalis toxicity.
Results from the present study are depicted on the right of the
fi gure. Patients from the present study were excluded from this
analysis if they lacked a pretreatmentserum potassium concentra-
tion determination, if they developed toxicity in the course of
clinical management with both digitalis and diuretic drugs or if
they died more than 4 days after ingestion of digitalis.
Discussion
Our clinical experience to date confirm s and extends the
data previously reported in 1982 (13) . Treatment of digoxin
and digitoxin toxicity with digox in-specific antibody frag-
ments is rapid and appears to be safe. The antibody frag-
ments had no demonstrable effects other than reversal of
the action of digitalis.
Relation of pretreatment potassium concentration to
outcome. Digitalis toxicity can cause a net loss of potas-
sium from cells by inactivating the cell membrane Na + -K +
ATPase pump. When toxicity is severe, serum potas sium
concentration rises . A clear relation between hyperkalemia
and fatal outcome was demonstrated in patients who ingested
large amounts of digitalis accidentally or with suicidal intent
and who received standard therapy for their toxicity (14).
Bismuth et al . (14) reviewed 91 episodes of acute digitalis
poisoning at the Paris Poison Control Center. They excluded
patients who were receiving therapy with diuretic drugs
at the time of ingestion and those who died more than 4
days after the ingestion. Their results are summarized in
Figure 4.
In the present study, no correlation existed between po-
tassium concentration before treatment and outcome. In fact,
most of the patients with hyperkalemia survived as a result
of treatment with digoxin antibody fragments. To compare
the results of our study with the experience of Bismuth et
SURVIVED EXPIRED
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al. (14),38 patients from our study were excluded from the
analysis in Figure 4. Nine patients lacked a pretreatment
serum potassium concentration determination, 23 patient s
developed toxicity in the course of clinical management with
digitalis and diuretic drug s and 6 patients died more than 4
days after ingestion of digitalis. By comparing the outcome
of the patients of Bismuth et al . with our results, it is evident
that digoxin-specific antibody fragments had a pronounced
effect on survival in our patients .
Response time. As suggested by the large volume of
distribution of Fab fragments compared with the intact garnma-
G globulin molecule in baboons (6) , and in keeping with
other experimental studie s in animals, clinical response to
digoxin-specific antibody fragments has been reasonably
rapid in almost all cases. One would expect response time
to be even faster with more rapid administration or use of
a larger dose of Fab fragments . On the other hand, admin-
istration of a larger dose subjects the recipient to a larger
and more prolonged antigenic stimulus and greater exposure
to potentially coadministered impurities , such as bacterial
endotoxins that might arise in processing of the Fab frag-
ments. Such impurities are minimized by the manufacturing
process, and detailed sterility and pyrogenicity testing is
done before clinical use. Where speed of action is essential
to the life of the patient , bolus administration of an ample
neutralizing dose seems a reasonable way to accelerate the
effect.
Safety of ovine Fab. From the inception of this effort
to develop a specific therapeutic agent for digitalis intoxi -
cation , special attention was given to the potential problems
associated with intravenous use of heterologous antibody
fragments in human beings . Thu s far, there has been no
evidence of acute hypersensitivity or delayed serum sickness
after use of ovine Fab fragments. We do not yet have any
experience with reexposure to purified digoxin-specific Fab
fragments.
Elimination of Fab fragments. Although the toxic and
pharmacologic actions of digoxin are neutralized by binding
to the ant ibody fragment whether or not this digo xin-Fab
fragment complex is removed from the body, elimination
of both digoxin and the antibody fragments is a matter of
concern . If the digoxin-Fab complex remains for a pro-
longed period in the body , immune degradation of the het-
erologous Fab might lead to re-release of free digoxin over
a period of a few days, with possible recrude scence of overt
toxicity .
In patients with good renal function , the digo xin-Fab
complex appears to be elim inated fairly rapidly by glomer-
ular filtration, usually with a half-life of about 16 to 20
hours. We were unable to obtain adequate serum samples
in patients with severe renal impairment to define the half-
lives of elimination of either digo xin or the Fab fragments
in such patients. However, with the exception of one patient
who received an inadequate Fab dose, we did not observe
•
•
•
SURVIVED EXPIRED
LBISMUTH·GAULTIERJ
9.0
8.0 •
••
';"" •
~ • •7.0 ..
::E •• •::) •a:
•UJ
~~ ..6.0 ... I
z '" r •UJE •::E- •• I~ I II •UJ •a: 5.0I-:- IUJ0: ••0. ••4.0
t •
•
lACC Vol. 5. No.5
May 1985:1IBA-I23A
WENGER ET AL.
DIGOXIN FAD TREATMENT OF DIGITALIS TOXICITY
123A
any recurrence of toxicity after response to the antibody
fragments. Many of our patients with abnormal renal func-
tion had excellent responses to antibody fragment treatment.
Experience with these Fab fragments in patients without
renal function is insufficient to permit comment.
Once the antibody fragments have been given, it is not
possible to follow the patient 's serum digoxin concentration
using routine radioimmunoassay methods (12,15). An ac-
curate determination of total digoxin concentration can be
obtained by first boiling the serum, but this measure does
not reflect the concentration of free and, therefore , active
digoxin in the body. Free digoxin concentrations can be
measured by equilibrium dialysis (12).
The presence of digoxin-specific antibody fragments in
the patient's blood also complicates the process of repeat
administration of digoxin in these patients . Elimination of
Fab fragments from the body may require a week or longer,
depending, as noted, on renal function , after which redi-
gitalization and use of standard serum digoxin concentration
assays for follow-up study can be instituted as needed .
Further experience. The digoxin antibody fragments
used in this study were supplied by Wellcorne Research
Laboratories, United Kingdom. Additional experience with
this material in other countries and with digoxin-specific
antibody fragments made by others support our conclusions .
A total of 40 such patients treated worldwide has been
reported (15-23), with apparent good response and no evi-
dence of hypersensitivity or other adverse reactions . If fur-
ther experience confirms the safety of the clinical use of
digoxin-specific antibody fragments, their use might be ex-
panded to first line therapy for any patient who requires
definitive treatment. Use of digoxin-specific Fab fragment s
for both diagnostic and therapeutic purposes in patients in
whom the diagnosis of digitalis toxicity is uncertain must
await further evidence supporting their safety and usefulness
in this setting.
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